Home › Trials › NCT06410209

Culturally-tailored mobile and social media program to increase physical activity in Hispanic/Latino adolescent and young adult childhood cancer survivors.

Walking Juntos: Developing and Testing a Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors

Phase 2 Interventional Children's Oncology Group · NCT06410209

This project will test whether a culturally tailored home-based physical activity program delivered via mobile tools and social media can help Hispanic/Latino adolescent and young adult childhood cancer survivors become more active.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment190 (estimated)
Ages15 Years to 20 Years
SexAll
SponsorChildren's Oncology Group Research network
Drugs / interventionsCAR T, chimeric antigen receptor, chemotherapy, radiation
Locations77 sites (Mesa, Arizona and 76 other locations)
Trial IDNCT06410209 on ClinicalTrials.gov

What this trial studies

The program is developed in two stages: first, an iterative process with about 20 Latinx AYA survivors (balanced by English and Spanish preference) to adapt the StepByStep intervention for cultural relevance and remote delivery. In stage two, a randomized controlled trial will enroll 170 Latinx AYA survivors who currently do not meet physical activity guidelines and randomize them to the culturally-tailored remote intervention versus a Fitbit-only control for 12 weeks. The primary outcome is change in moderate-to-vigorous physical activity (MVPA) measured continuously with a validated Fitbit tracker, with secondary outcomes including sedentary time and self-reported health-related quality of life. The intervention combines goal-setting, motivational content delivered by mobile/social media, and remote coaching components tailored to language and cultural preferences.

Who should consider this trial

Good fit: Ideal candidates are Hispanic/Latino AYA childhood cancer survivors aged 15 to under 21 who are in first continuous remission, completed chemotherapy and/or radiation 3–36 months ago, prefer English or Spanish, and report under 420 minutes of moderate-to-vigorous physical activity per week.

Not a fit: Patients who already meet physical activity guidelines, are outside the 15–20 age range, are not in first remission, have excluded transplant procedures or medical limitations that prevent activity, or are not able to use mobile devices may not receive benefit from this intervention.

Why it matters

Potential benefit: If successful, the program could help participants increase moderate-to-vigorous physical activity, reduce sedentary time, and improve quality of life, potentially lowering long-term health risks.

How similar studies have performed: Wearable and mobile health programs have shown modest success increasing activity in other populations, but culturally-tailored remote interventions specifically for Latino AYA childhood cancer survivors are relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patient must be ≥ 15 years and \< 21 years at the time of enrollment
* First diagnosis of malignant neoplasm (International Classification of Diseases for Oncology \[ICD-O\] behavior code of "3") in first and continuous remission at the time of enrollment
* Curative cancer treatment must have included chemotherapy (including cellular therapy) and/or radiation (including radioactive iodine). Note: Certain stem cell transplant procedures are excluded. Reminder: Children's Oncology Group (COG) therapeutic trial participation is not required
* Completed all chemotherapy and/or radiation therapy in the last 3-36 months. This includes completion of all oral (e.g., tyrosine kinase inhibitors) and/or maintenance chemotherapy
* Self-report of \< 420 minutes of moderate-to-vigorous physical activity per week as assessed and documented via the study-specific Physical Activity Worksheet. Note: See the case report forms packet on the COG study web page for the study specific Physical Activity Worksheet
* Ambulatory and no known medical contraindications to increasing physical activity
* No known significant physical or cognitive impairment that would prevent use of the electronic devices used for the protocol intervention (e.g., Fitbit, smartphone, tablet, or computer)
* Able to read and write Spanish or English
* Self-identify as Hispanic, Latino/Latina/Latinx

Exclusion Criteria:

* Patients with previous allogeneic hematopoietic stem cell transplant (HSCT) are excluded. Note: Patients with previous autologous HSCT, chimeric antigen receptor T-cell (CAR T-cell) therapy, and other cellular cancer therapies can participate as long as all other eligibility criteria are satisfied
* Post-menarchal female patients who are pregnant or planning to become pregnant in the next year are excluded. Note: Pregnancy status can be established by clinical history with patient. Post-menarchal female patients are eligible as long as they agree to use an effective contraceptive method (including abstinence) during study participation
* Participants who were enrolled in ALTE2031 (Step by Step) cannot enroll in ALTE2321. Participants who were enrolled in ALTE2321 stage 1 (cultural tailoring) cannot enroll to participate in stage 2 (RCT)
* All patients and/or their parents or legal guardians must sign a written informed consent. Note: Informed consent may be obtained electronically/online if allowed by local site policy and institutional review board (IRB)/research ethics board (REB) of record
* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

Where this trial is running

Mesa, Arizona and 76 other locations

+27 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Hematopoietic and Lymphatic System NeoplasmMalignant Solid Neoplasm
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.